GlassScriptPhysician profile
Annie V Truong
NPI 1386157642
$5,525.02
in general payments reported to CMS, 2019-2025
23 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $721 · 2023: $2,732 · 2024: $903 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.81 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,891.68 | 2023 | Cabometyx |
| Incyte Corporation | $1,612.31 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $426.98 | 2021-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $256.52 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $236.91 | 2021-2024 | Fotivda |
| Abbvie INC. | $184.16 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $173.34 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $142.09 | 2021-2023 | Imbruvica |
| Novocure INC. | $140.52 | 2022 | |
| Emd Serono, INC. | $67.62 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $59.88 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Janssen Biotech, INC. | $50.96 | 2024 | Rybrevant, Talvey, Tecvayli |
| Recordati_rare_diseases_inc. | $46.30 | 2023-2024 | Sylvant |
| Tersera Therapeutics LLC | $34.36 | 2024 | Zoladex |
| Spectrum Pharmaceuticals INC. | $33.28 | 2024 | Rolvedon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.90 | 2024 | Enhertu |
| Blueprint Medicines Corporation | $24.83 | 2024 | Ayvakit |
| Fennec Pharmaceuticals, INC. | $22.66 | 2024 | Pedmark |
| Eisai INC. | $21.43 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.38 | 2025 | Danziten |
| Sobi, INC | $18.14 | 2021 | |
| Olympus America INC. | $16.65 | 2024 | Evis Exera III Duodenovideoscope |
| Shorla Oncology INC. | $15.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.